The Catalyst Set

The Catalyst Set – Retatrutide 30 mg + GHK-Cu 50 mg + CJC-1295 (No DAC) / Ipamorelin 10 mg

For In Vitro Research Use Only
Not for Human or Veterinary Application

Set Overview

The Catalyst Set is a multi-pathway research panel combining a triple-receptor incretin / glucagon agonist, a copper-binding tripeptide, and a co-formulated GH-axis blend. Retatrutide is a synthetic acylated peptide and triple agonist at the GLP-1, GIP, and glucagon receptors. GHK-Cu is the copper-binding tripeptide Glycyl-L-Histidyl-L-Lysine·Cu(II), studied for collagen, glycosaminoglycan, and metalloproteinase expression modulation in fibroblast and keratinocyte cultures. The CJC-1295 (No DAC) + Ipamorelin component is a co-lyophilized blend (5 mg + 5 mg) combining a GHRH(1-29) analog with a selective ghrelin receptor (GHSR-1a) agonist for dual-mechanism GH-axis research. Each component ships as its own individually-labeled vial of lyophilized powder, third-party verified at ≥99% purity per compound.

Components

• Retatrutide — 30 mg · CAS 2381089-83-2 · MW 4,969.6 Da · GLP-1 / GIP / GCG triple receptor agonist · Purity ≥99.4%

• GHK-Cu — 50 mg · Glycyl-L-Histidyl-L-Lysine·Cu(II) · Lyophilized powder · Purity ≥99%

• CJC-1295 (No DAC) + Ipamorelin — 10 mg blend · CJC-1295 (No DAC) 5 mg, CAS 863288-34-0, MW ~3,367.1 Da · Ipamorelin 5 mg, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4, MW ~711.9 Da · Purity ≥99.4% per component

• Form: Lyophilized Powder (each vial)

• Storage: -20°C long-term; 4°C short-term (use within 4 weeks of reconstitution)

Research Context

Retatrutide activates GLP-1R, GIPR, and GCGR — three class B G protein-coupled receptors governing insulin secretion, gluconeogenesis suppression, lipolysis, and thermogenesis — making it a research tool of interest in studies of energy expenditure, hepatic lipid metabolism, and incretin-glucagon signaling integration. GHK-Cu binds copper(II) and is studied for its effects on collagen synthesis, decorin and elastin expression, MMP-1 / MMP-2 modulation, and antioxidant / Nrf2 pathway activation in dermal fibroblast and keratinocyte cultures. The CJC-1295 (No DAC) + Ipamorelin blend operates through two complementary GH-axis mechanisms: CJC-1295 (No DAC) activates the GHRH receptor via Gαs / cAMP / PKA signaling, stimulating GH gene transcription and somatotroph release, while Ipamorelin selectively activates GHSR-1a through a Gαq / IP3 / Ca²⁺ pathway, with high specificity that avoids ACTH, cortisol, and prolactin-releasing pathway co-activation. Together the three components enable parallel study of metabolic regulation (Retatrutide), connective-tissue / regenerative biology (GHK-Cu), and pituitary GH-axis signaling (CJC-1295 / Ipamorelin) in shared experimental workflows.

Note on Retatrutide dosing. The Retatrutide vial in this set is the 30 mg presentation. The 10 mg vial featured in the bundle photography is temporarily out of stock and we are working to restock it. Once 10 mg is back in stock, this set will switch back to the 10 mg vial. The current bundle price has been adjusted to reflect the 30 mg substitution.

Intended Use

This set is intended strictly for in vitro laboratory research by qualified professionals.
It is not approved for:

• Human use

• Veterinary use

• Food, drug, diagnostic, or cosmetic applications

Regulatory Disclaimer

• These compounds have not been evaluated by the U.S. Food and Drug Administration (FDA).

• They are not intended to diagnose, treat, cure, or prevent any disease.

• All handling and use must comply with applicable institutional, local, state, and federal regulations.

Terms of Sale

By purchasing from Axis Peptide Labs, the buyer confirms that they are a qualified researcher, laboratory, or institution and acknowledges that the products are for research use only.

• All sales are final.

• The purchaser assumes full responsibility for compliant handling, storage, and use.

• Resale for human consumption is strictly prohibited.